Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

IMPORTANCE: Current treatments for long-term prophylaxis in hereditary angioedema have limitations. OBJECTIVE: To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks. DESIGN, SETTING, AN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2018-11, Vol.320 (20), p.2108-2121
Hauptverfasser:	Banerji, Aleena, Riedl, Marc A, Bernstein, Jonathan A, Cicardi, Marco, Longhurst, Hilary J, Zuraw, Bruce L, Busse, Paula J, Anderson, John, Magerl, Markus, Martinez-Saguer, Inmaculada, Davis-Lorton, Mark, Zanichelli, Andrea, Li, H. Henry, Craig, Timothy, Jacobs, Joshua, Johnston, Douglas T, Shapiro, Ralph, Yang, William H, Lumry, William R, Manning, Michael E, Schwartz, Lawrence B, Shennak, Mustafa, Soteres, Daniel, Zaragoza-Urdaz, Rafael H, Gierer, Selina, Smith, Andrew M, Tachdjian, Raffi, Wedner, H. James, Hebert, Jacques, Rehman, Syed M, Staubach, Petra, Schranz, Jennifer, Baptista, Jovanna, Nothaft, Wolfram, Maurer, Marcus
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Angioedema Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Child Clinical trials Disease prevention Double-Blind Method Edema Effectiveness Female Females Hereditary Angioedema Types I and II - classification Hereditary Angioedema Types I and II - prevention & control Humans Impact analysis Injections, Subcutaneous - adverse effects Kallikrein Male Middle Aged Monoclonal antibodies Original Investigation Patients Placebo effect Plasma kallikrein Plasma Kallikrein - antagonists & inhibitors Prophylaxis Quality of Life Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!